Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas

Fig. 3

AZD5991 resistance induction, siRNA knockdown, and IP of BIM show a synergistic effect of MCL-1 and BCL-xL. A Western blot showing upregulation of MCL-1 and BCL-xL in AZD5991 resistant 1889c (1889c-AZDr). B Cell viability assays of 1889c, 1889c-AZDr, and resistant cells after cessation of treatment (1889c-AZDr/w) show partial reversibility of the induced AZD5991 resistance. C 1889c-AZDr and 1889c-AZDr/w show no increased sensitivity towards single treatment with A-1155463 (0.05μM) and ABT-263 (0.5μM) but D are sensitive towards a combinational treatment with AZD5991 (0.5μM). E Western blot analysis and F cell viability assay of 1889c after MCL-1 and BCL-xL knockdown with two individual siRNAs. G Cell viability assay of 1889c after BCL-xL knockdown and treatment with AZD5991 (0.5μM). H Cell viability assay of 1889c after MCL-1 knockdown and 24-h treatment with A-1155463 (0.05μM) or ABT-263 (0.5μM). I Redistribution of BIM in 1889c cells after 4-h treatment with AZD5991 (0.1μM), A-1155463 (0.1μM), or a combination of both (western blot after BIM IP)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us